黄喉拟水龟转铁蛋白基因的克隆以及表达特征分析

转铁蛋白在铁的新陈代谢中起着重要的作用,参与细菌感染后的免疫反应。研究克隆了黄喉拟水龟Tf基因组DNA全长序列,并对Tf基因的序列特征进行了分析。序列分析表明,黄喉拟水龟Tf是由两个相似结构域构成的单一肽链,每个结构域包含两个亚基,它们相互作用形成一个深的、亲水的铁结合位点。其基因组DNA由17个外显子和16个内含子组成,与其他脊椎动物Tf基因结构相似,显示了黄喉拟水龟Tf基因在结构上的保守性。同源性分析表明,黄喉拟水龟的Tf基因与鸟类、爬行类的Tf基因同源性最高,约为75%—97%;与哺乳类Tf基因的同源性约为65%—75%;与爪蟾等两栖类的Tf基因也有一定的同源性。荧光定量PCR结果显示,黄喉拟水龟人工感染粘质沙雷氏菌后,Tf基因在其肝脏、脾脏、肾脏及心脏各组织中的表达量均有上调的趋势,这与其他动物经病原刺激后的表达特征具有相似性。       

II型鲤疱疹病毒ORF4的多克隆抗体制备及其组织分布

【目的】制备II型鲤疱疹病毒(Cy HV-2)ORF4多克隆抗体,利用免疫学方法研究ORF4编码蛋白在病毒感染过程中的组织表达特征。【方法】利用在线软件SMART和BLASTx分析Cy HV-2 ORF4序列,采用PCR技术从Cy HV-2基因组中扩增得到ORF4基因,克隆至表达载体PGEX-4T-3中,将获得的重组表达质粒转化到大肠杆菌BL21(DE3)中,用IPTG诱导表达,表达产物经过SDS-PAGE和Western blot鉴定,再利用亲和层析法纯化出重组蛋白。用纯化的重组ORF4蛋白免疫新西兰兔,收集兔血,分离兔血清获得抗ORF4蛋白的多克隆抗体,再利用Western blot检测抗体与ORF4蛋白之间的特异性。提取攻毒后的异育银鲫肌肉、脑、鳃、脾脏、肝胰脏、心脏、肾脏等组织DNA,用荧光定量PCR技术监测其病毒在各组织的复制水平。使用RIPA裂解液提取上述各组织总蛋白,再利用Western blot技术检测ORF4在感染Cy HV-2的异育银鲫各组织中的表达情况。【结果】原核表达的重组ORF4蛋白分子量为65 k D,与预期大小一致;获得的ORF4抗血清能特异性识别重组ORF4蛋白。病毒感染的异育银鲫体内ORF4主要表达在肾脏、脾脏和鳃上;荧光定量PCR证明Cy HV-2主要在肾脏、脾脏和鳃上富集。【结论】Cy HV-2的非结构蛋白ORF4可能参与病毒的复制,是病毒复制感染周期的特征性指示蛋白之一,这为深入研究ORF4在Cy HV-2感染过程中的作用机制提供参考。     

沙门菌毒力基因spvB的原核表达及其多克隆抗体的制备

目的:构建沙门菌毒力基因spvB的原核表达载体,诱导表达纯化SpvB蛋白并以其为抗原免疫小鼠,制备多克隆抗体。方法:利用生物信息学软件对SpvB进行分析,选取抗原性较高、易表达的氨基酸序列作为克隆序列,以携带spvB基因的鼠伤寒沙门菌为模板,PCR扩增目的片段后与原核表达载体pET28a(+)连接;将质粒pET28a-SpvB转化大肠埃希菌BL21(DE3)后诱导表达并纯化。目的蛋白免疫小鼠,制备抗SpvB多克隆抗体,Western blot检测抗体特异性。结果:成功构建spvB原核表达载体,经IPTG诱导结果显示,重组蛋白表达且主要存在于包涵体中,将纯化后的蛋白免疫小鼠Western blot检测血清中抗体与SpvB特异性结合。结论:获得具有免疫原性的SpvB蛋白及其多克隆抗体,为进一步研究该基因的功能奠定基础。     

人FGF21原核表达载体的构建及重组蛋白表达

构建人FGF21(fibroblast growth factor,FGF)cDNA的原核表达载体并诱导其重组蛋白表达。提取人肝脏总RNA后,经RT-PCR扩增获得目的片段,构建其T载体进行保存。再构建重组原核表达载体pET-28a(+)-h FGF21,重组质粒转化至大肠杆菌菌株BL21(DE3)中,在IPTG诱导下得到可溶性表达,采用亲和层析法纯化表达产物后,进行Western blot鉴定。成功构建重组质粒pET-28(+)-hFGF21,对其进行可溶性表达后成功纯化出his-hFGF21,经Western blot鉴定该融合蛋白可与FGF21抗体特异性结合。成功构建pET-28(+)-hFGF21,并可溶性表达his-hFGF21蛋白。     

炭疽菌保护性抗原受体结合区的表达及其多克隆抗体的制备

原核表达炭疽杆菌保护性抗原受体结合区并制备该蛋白的多克隆抗体.从炭疽芽胞杆菌A16R中经PCR扩增得到了炭疽菌保护性抗原(PA)受体结合区基因,即PA的第四结构域(PA-D4),将其克隆至含有6×His编码序列的原核表达载体pET-2b(+)中,将重组质粒转化大肠杆菌BL21(DE3),在IPTG诱导下进行蛋白表达;用HiTrapTM Chelating HP柱纯化重组蛋白,Western blot进一步鉴定;以纯化后的蛋白为抗原,免疫新西兰大耳白兔制备该蛋白的多克隆抗体;用ELISA和Western blot检测抗血清.结果表明,目的蛋白在大肠杆菌BL21(DE3)中获得了可溶性表达,纯化后纯度可达90%以上;制备了针对PA-D4融合蛋白的高效价抗血清,ELISA抗体滴度为1∶ 102 400;其抗体能特异性识别内源性的PA.PA-D4重组蛋白及其多克隆抗体的获得,为后续研究其功能和炭疽疫苗免疫保护机制奠定了基础.     

Flt3配体胞外域的原核表达纯化及活性鉴定

目的:构建pET32a(+)-hFLext原核表达载体,诱导hFLext蛋白表达、纯化及活性鉴定.方法:以人淋巴细胞cDNA文库为模板,克隆hFlext,构建pET32a(+)-hFLext重组表达载体.转化大肠杆菌BL21,IPTG诱导蛋白表达,镍珠亲合层析纯化蛋白,SDS-PAGE及Western blot鉴定.细胞增殖实验检测其生物学活性.结果:成功克隆获得hFLext,并构建了pET32a(+)-hFLext重组表达载体.在大肠杆菌BL21,经1 mM IPTG 30℃诱导12 h,成功表达Trx-hFLext融合蛋白,主要以包涵体形式存在.经8M尿素变性包涵体蛋白,逐步透析复性,镍珠亲合层析纯化蛋白,SDS-PAGE及Western blot鉴定,成功获得高纯度的Trx-hFLext融合蛋白.细胞增殖实验证实其具有生物学活性,能够有效刺激脐血细胞增殖.结论:成功构建了pET32a(+)-hFLext重组表达载体,表达、纯化了具有生物学活性的Trx-hFLext融合蛋白,为造血干/祖细胞的体外扩增研究奠定了基础.     

果蝇odd蛋白的原核表达及多克隆抗体的制备研究

odd是一个新发现的心脏特异表达基因。为了进一步研究odd在心脏发育中的功能,根据已报道的odd基因序列,以果蝇cDNA文库为模板进行PCR扩增,将所得的odd部分编码区序列连接到pET-28a载体上构建原核表达载体;重组子经酶切测序鉴定后,转化到大肠杆菌BL21菌株,IPTG诱导融合蛋白表达,Ni-IDA凝胶柱亲和纯化,纯化后的His-odd融合蛋白免疫新西兰大白兔以制备多克隆抗体,Western Blot检测抗体活性。结果表明,获得了odd原核表达重组融合蛋白以及高效价的、特异性兔抗Odd多克隆抗体,为后续的odd功能研究奠定了基础。     

炭疽芽孢杆菌EA1蛋白的融合表达和纯化

目的：原核表达重组炭疽芽孢杆菌EA1蛋白。方法：用PCR方法从炭疽芽孢杆菌A16R疫苗株染色体中扩增编码EA1蛋白的eag基因序列,经过纯化、酶切后克隆到含有GST标签的原核表达载体pGEX-6P-2中,构建重组载体pGEX-EA1;将空载体（作为对照）、重组载体转化大肠杆菌BL21（DE3）菌株获得表达工程菌株,对其表达和纯化条件进行优化;利用Western印迹检测融合蛋白的表达。结果：构建了EA1蛋白的融合表达载体,并在大肠杆菌中获得高效表达;经Glutathione Sepharose 4B纯化获得了EA1蛋白;Western印迹表明,此蛋白可与GST标签抗体反应。结论：在原核表达系统中表达并纯化得到EA1融合蛋白,为进一步对其进行功能研究奠定了基础。     

GST-Ets-1融合蛋白的表达与纯化

[目的]旨在原核表达Ets-1基因,纯化获得GST-Ets-1融合蛋白。[方法]以SD大鼠脑垂体cDNA为模板,利用PCR扩增含有Bam HI和Not I酶切位点的Ets-1基因;然后将其克隆到pGEX-4T-1原核表达载体中,将正确的重组载体转入大肠杆菌BL21(DE3);用IPTG诱导表达,再利用Magne GST particles亲和纯化GST-Ets-1融合蛋白;最后通过Western blot鉴定此融合蛋白。[结果]成功构建pGEX-4T-1-Ets-1原核表达载体;30℃条件下,0.2 mmol/L的IPTG能诱导出大量的可溶性GST-Ets-1蛋白;经Magne GST particles纯化的GST-Ets-1蛋白可被识别ETS-1的抗体特异识别。[结论]纯化的GST-Ets-1蛋白可用于后续的生物学研究。     

GST-Smad4融合蛋白的表达与纯化

旨在原核表达Smad4基因,纯化获得GST-Smad4融合蛋白。以人表皮HaCaT细胞的cDNA为模板,利用PCR扩增含有BamH I和SalI酶切位点的Smad4基因;然后将其克隆到pGEX-4T-1原核表达载体中,将正确的重组载体转入大肠杆菌BL21(DE3);用IPTG诱导表达,再利用MagneGST particles亲和纯化GST-Smad4融合蛋白;最后通过Western blot鉴定此融合蛋白。结果显示,成功构建pGEX-4T-1-Smad4原核表达载体;30℃条件下,0.2 mmol/L的IPTG能诱导出大量的可溶性GST-Smad4蛋白;经MagneGST particles纯化的GST-Smad4蛋白可被Smad4的抗体特异识别。纯化的GST-Smad4蛋白可用于后续的生物学研究。     

抑菌蛋白Reg3A的表达纯化与功能

利用原核表达系统表达人源抑菌蛋白Reg3A,经包涵体的复性和纯化获得有体外抑菌功能的活性抑菌蛋白,并对其体外抑菌功能进行初步研究。构建Reg3A原核表达载体PET-32a-Reg3A转化补充稀缺tRNA基因的表达菌株大肠杆菌BL21-Codonplus,阳性重组子采用诱导培养基诱导5h后,采用超声破碎的方法提取包涵体蛋白,经包涵体蛋白的纯化和透析复性后通过Ni-NTA亲和层析交换柱,获得纯度达95%的蛋白质。Western blot鉴定显示在15 kD处有特异性条带。使用纯化后的蛋白进一步进行抑菌圈实验和抑菌活性实验,对获得蛋白的体外抑菌活性进行评估,从而为进一步进行Reg3A蛋白功能的评估及应用奠定基础。     

Purification, refolding, and characterization of recombinant LHRH-T multimer

To make the native LHRH immunogenic, a multimer of LHRH interspersed with T non-B peptides (r-LHRH-d2) was expressed as recombinant protein in Escherichia coli. The expression level of the recombinant protein was around 15% of the total cellular protein and it aggregated as inclusion bodies. Inclusion bodies from the bacterial cells were isolated and purified to homogeneity. Instead of high concentrations of chaotropic agents, r-LHRH- d2 was solubilized in 50 mM citrate buffer at pH 3 containing 2 M urea. The protein was refolded by 5-fold dilution (pulsatile) with cold 10 mM citrate buffer at pH 6 in presence of 0.3 M L-arginine. Purification of r-LHRH-d2 was carried out by successive passages on CM-Sepharose column at pH 6.0 which retained extraneous proteins and pH 4.8 at which r-LHRH-d2 bound to the resin. The elution was carried out by using linear salt gradient (0.1-1 M NaCl). The overall yield of the purified r-LHRH-d2 was 40% of the initial inclusion body proteins. The purity and homogeneity were confirmed by a single homogeneous peak on analytical HPLC eluting out at 29.51 min and by single band on SDS-PAGE reactive with polyvalent anti-LHRH antibodies. Mass spectroscopic analysis indicated the protein to be of 16.6 kDa which equals the theoretically expected mass. The N-terminal amino acid analysis of r-LHRH-d2 showed the sequence which corresponded to the designed protein. The CD spectrum of the refolded r-LHRH-d2 showed that the multimer has considerable beta sheet structure like the monomeric LHRH protein.     

人NMDA受体主亚基M3-M4环基因片段的高效表达、纯化与鉴定

用基因工程方法获得人N 甲基 D 天冬氨酸 (N methyl D aspartate ,NMDA)受体主亚基M3 M4环靶片段 ,以此为免疫原 ,用于进一步免疫原性及相关应用研究 .自人脑胶质瘤组织中提取总RNA ,采用RT PCR扩增出人NMDA受体主亚基M3 M4环的基因片段 ,并按照计算机辅助原核表达载体pBV2 2 0中外源基因高效表达的数学模型预测方法 ,将其进行优化改构 .将目的基因克隆到pBV2 2 0中 ,转化大肠杆菌DH5α ,升温诱导表达 ,从蛋白质水平检测重组体在大肠杆菌中的表达情况 ,通过制备性SDS PAGE进行纯化 ,从相对分子质量、免疫反应性、肽质谱指纹分析等方面进行鉴定 .结果表明 ,成功构建了人NMDA受体主亚基M3 M4环的原核表达载体 (命名为pBV NR1L3) ,通过基因优化 ,实现了高效表达 .凝胶扫描分析表达量约占菌体总蛋白 2 9% ,重组肽纯度达 95 %以上     

Cloning and purification of functionally active Fas ligand interfering protein (FIP) expressed in Escherichia coli

This report presents purification and characterization of the extracellular domain of rat Fas protein, called FIP (FasL interfering protein), expressed as inclusion bodies in Escherichia coli. FIP was extracted from the inclusion bodies, solubilized with 8 M urea, purified by a single-step immobilized metal ion (Ni(2+)) affinity chromatography and refolded. SDS/PAGE and mass spectrometry analysis of the purified protein verified its purity. Fluorescence spectrum analysis showed that the refolding procedure caused structural changes which presumably might have led to oligomerization. The purified FIP has biological activities: it binds specifically soluble Fas ligand and protects human Jurkat lymphocytes against FasL-dependent apoptosis. This efficient procedure of FIP expression in E. coli and renaturation may be useful for production of therapeutically important proteins.     

Purification of an active monomeric recombinant HIV-1 trans-activator.

A method for the purification of a truncated, biologically active human immunodeficiency virus type 1 (HIV-1) trans-activator (rTAT) from recombinant Escherichia coli is reported here. The purification steps utilized include mild extraction (French press), concentration by ammonium sulfate precipitation, chromatography in 8 M urea on an S-Sepharose fast-protein liquid chromatography column, and finally, resolution by C-4 reverse-phase high-performance liquid chromatography. After the final step, the rTAT is dried and stored under salt-free conditions. Amino acid compositional analysis and N-terminal sequence analysis confirm that the purified protein is rTAT. Unlike other methods reported for purification of recombinant HIV-1 trans-activator, our protocol uses urea instead of guanidine HCl. The rTAT is fully soluble in buffered solutions at concentrations exceeding 10 mg/ml, migrates as a single 14 kDa species on both sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE) and two-dimensional PAGE gels with a pI of 9.3 +/- 0.3. Additionally, the rTAT migrates as a monomer on size-exclusion chromatography columns under native conditions. Finally, purified rTAT exhibits trans-activator activity when introduced into appropriate reporter cells. Since rTAT is monomeric when tested by gel filtration, and yet exhibits biological activity, we conclude that the method of purification we have utilized is distinct from all other methods reported to date.     

Expression, purification, and refolding of a novel immunotoxin containing humanized single-chain fragment variable antibody against CTLA4 and the N-terminal fragment of human perforin

Immunotoxins might be potential in treatment of cancer for their ability to kill selected cell populations. We constructed a novel immunotoxin hS83P34 by fusing N-terminal 34 amino acid fragment of human perforin to the C-terminus of humanized single-chain fragment variable antibody against CTLA4. The fusion protein was inductively expressed as inclusion bodies at a high level about 30% of total bacterial proteins. After washing with buffer containing 2 M urea, the purity of inclusion body was about 71%. The washed inclusion bodies were solubilized in 8 M urea and further purified to homogeneity (approximately 92% purity) by cation-exchange chromatography and Ni-agarose affinity chromatography under denaturing condition. The inclusion body refolding conditions were optimized following Pro-Matrix Protein Refolding Guide. After refolded in Tris buffer (pH 8.0) containing 1M urea, 0.8 M l-arginine, and 2 mM GSH:0.2 mM GSSG or 2 mM GSH:0.4 mM GSSG for 18h at 4 degrees C, over 90% proteins were recovered from inclusion bodies. In vitro dose-dependent cytotoxicity assay demonstrates that hS83P34 is only toxic to CTLA4-positive cells. IC(50) of hS83P34 for leukemic cells Raji and 6T-CEM are about 0.85 and 1.3 microM individually. Whereas, CTLA4-negative endothelial cell ECV-304 is resistant to hS83P34.     

Non-reducing alkaline solubilization and rapid on-column refolding of recombinant prion protein

Mature prion protein (PrP) is a 208-residue polypeptide that contains a single disulfide bond. We report an alternative method to purify recombinant mouse PrP produced in Escherichia coli. Bacterial inclusion bodies were solubilized in a buffer containing 2 M urea at pH 12.5. The solubilized protein was rapidly purified on a nickel affinity column without a chaotrope gradient, followed by ion-exchange chromatography. The yield and purity of PrP produced by this alternative approach was similar to that obtained using a conventional solubilization and on-column refolding protocol. Recombinant PrP produced using the non-reducing purification protocol is properly folded, as determined by circular dichroism, and a competent substrate for amyloid fibril formation, as determined by Thoflavin-T dye binding assays. In summary, this report describes a rapid method for producing properly folded recombinant PrP without reducing agents or a chaotrope gradient.     

Bacterial production and purification of recombinant human prolactin

Escherichia coli cells transformed with a recombinant plasmid (pT7L) containing the coding sequence of human prolactin (hPrl) expressed a new protein. This protein, comigrating with human Prl on sodium dodecyl sulfate (SDS)-polyacrylamide gels, represented 50% of the total bacterial extract. Immunoprecipitation of [35S]methionine-labeled bacterial lysate with a rabbit antiserum to hPrl followed by SDS-polyacrylamide gel electrophoresis (PAGE) analysis showed that the major component had a Mr identical to that of standard hPrl. The majority of the recombinant hPrl (r-hPrl) accumulated in inclusion bodies. Analysis of these inclusion bodies by SDS-PAGE under nonreducing conditions showed that they are composed mostly of fully reduced monomers. Solubilization of the inclusion bodies and protein denaturation were performed in 8 M urea. Refolding during the renaturation procedure was confirmed by SDS-PAGE under nonreducing conditions. r-hPrl was further purified by gel permeation chromatography on a fast protein liquid chromatography column. More than 95% of the molecules were recovered as oxidized monomeric forms. The refolded molecule was tested for its bioactivity in the Nb2 lymphoma mitogenic assay. The dose-response curves obtained with either r-hPrl or pituitary-derived hPrl showed a complete parallelism. Furthermore, Nb2 cell proliferation was completely blocked by addition of hPrl antiserum to both preparations. Recombinant hPrl is identical to natural hPrl except for an additional methionine group at the amino terminal end.     

Cloning, expression, and refolding of a secretory protein ESAT-6 of Mycobacterium tuberculosis

A DNA encoding the 6-kDa early secretory antigenic target (ESAT-6) of Mycobacterium tuberculosis was inserted into a bacterial expression vector of pQE30 resulting in a 6x His-esat-6 fusion gene construction. This plasmid was transformed into Escherichia coli strain M15 and effectively expressed. The expressed fusion protein was found almost entirely in the insoluble form (inclusion bodies) in cell lysate. The inclusion bodies were solubilized with 8M urea or 6M guanidine-hydrochloride at pH 7.4, and the recombinant protein was purified by Ni-NTA column. The purified fusion protein was refolded by dialysis with a gradient of decreasing concentration of urea or guanidine hydrochloride or by the size exclusion protein refolding system. The yield of refolded protein obtained from urea dialysis was 20 times higher than that from guanidine-hydrochloride. Sixty-six percent of recombinant ESAT-6 was successfully refolded as monomer protein by urea gradient dialysis, while 69% of recombinant ESAT-6 was successfully refolded as monomer protein by using Sephadex G-200 size exclusion column. These results indicate that urea is more suitable than guanidine-hydrochloride in extracting and refolding the protein. Between the urea gradient dialysis and the size exclusion protein refolding system, the yield of the monomer protein was almost the same, but the size exclusion protein refolding system needs less time and reagents.     

Simultaneous refolding and purification of a recombinant lipase with an intein tag by affinity precipitation with chitosan

A strategy for simultaneous purification and refolding of proteins overexpressed with an intein tag is described. A recombinant lipase overexpressed in Escherichia coli ER2566 with the intein tag and obtained as inclusion bodies was solubilized in buffer containing 8 M urea or cetyltrimethylammonium bromide. The solubilized lipase was precipitated with chitosan and the affinity complex of the polymer with the fusion protein was obtained. The intein tag was cleaved with dithiothreitol and the refolded lipase was obtained in active form. Activity recovery of 80% was observed and the enzyme had a specific activity of 2965 units/mg. The purified lipase showed a single band on sodium dodecyl sulfate polyacrylamide gel electrophoresis. The purity and activity recovery were comparable with that of the preparation obtained by using the commercial kit which utilizes chromatography on chitin beads. The purified and refolded lipase was characterized by fluorescence and CD spectroscopy.